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Abstract
Aims/hypothesis The aim of the present study was to
investigate the effect of blood pressure lowering and
intensive glucose control on the incidence and progression
of retinopathy in type 2 diabetic patients.
Methods The Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation (AD-
VANCE) Retinal Measurements study, a substudy of
ADVANCE, is a randomised (using a central, computer-
based procedure) controlled 2×2 factorial trial comprising a
double-blind comparison of blood pressure lowering with
perindopril–indapamide vs placebo, and an open compari-
son of standard vs intensive glucose control targeting a
HbA1c of≤6.5% in 1,602 diabetic patients from ADVANCE
centres with access to retinal cameras conducted from 2001
to 2008. At baseline and the final visit, seven-field
stereoscopic retinal photographs were taken and graded by
blinded readers (gradeable baseline and final photographs
from 1,241 patients). Progression of ≥2 steps in the Early
Treatment of Diabetic Retinopathy Study classification
(using the eye with worst grading) was the primary
outcome.
Results Retinopathy progressed in 59 (4.8%) patients and
developed in 128 (10.3%) patients over 4.1 years. Fewer
patients on blood pressure-lowering treatment (n=623)
experienced incidence or progression of retinopathy com-
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found in the Electronic supplementary material.
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pared with patients on placebo (n=618), but the difference
was not significant (OR 0.78; 95% CI 0.57–1.06; p=0.12).
Blood pressure-lowering treatment reduced the occurrence
of macular oedema (OR 0.50; 95% CI 0.29–0.88; p=0.016)
and arteriovenous nicking compared with placebo (OR
0.60; 95% CI 0.38–0.94; p=0.025). Compared with
standard glucose control (n=611), intensive glucose control
(n=630) did not reduce (p=0.27) the incidence and
progression of retinopathy (OR 0.84; 95% CI 0.61–1.15).
Lower, borderline significant risks of microaneurysms, hard
exudates and macular oedema were observed with intensive
glucose control, adjusted for baseline retinal haemorrhages.
These effects of the two treatments were independent and
additive. Adverse events in the ADVANCE study are
reported elsewhere.
Conclusions/interpretation Blood pressure lowering or in-
tensive glucose control did not significantly reduce the
incidence and progression of retinopathy, although consis-
tent trends towards a benefit were observed, with signifi-
cant reductions in some lesions observed with both
interventions.
Trial registration' ClinicalTrials.gov ID no. NCT00145925.
Funding' Grants from Servier and the National Health and
Medical Research Council of Australia
Keywords Blood pressure lowering . Diabetic retinopathy .
Intensive glucose control
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Introduction
By 2030, an estimated 350 million people will have type 2
diabetes worldwide [1]. Diabetic retinopathy is a progres-
sive disorder of the retinal microcirculation and is the
most common cause of blindness among people aged
30–69 years [2, 3].
Both blood pressure and blood glucose are continuously
associated with a risk of diabetic retinopathy [4–7]. The UK
Prospective Diabetes Study (UKPDS) is the only intervention
study to date of sufficient size to study the effect of glucose
and blood pressure lowering on retinopathy in diabetic
patients. It showed that improved glucose control reduced
the risk of microvascular disease by 25% [8]. However, that
effect was found only after the start of an additional
antihypertensive trial, 10 years after the glycaemic arm
began [8]. Among the 1,148 hypertensive UKPDS patients,
tight blood pressure control reduced the incidence and
progression of retinopathy by 34% after 7.5 years [9, 10].
The UKPDS was restricted to newly diagnosed patients
predominantly of European origin and the blood pressure-
lowering arm was restricted to hypertensive patients. Blood
pressure-lowering agents can be used irrespective of initial
blood pressure level or the use of other antihypertensive
medications. This would produce a smaller average blood
pressure reduction than that seen in the UKPDS, but would
shift the blood pressure distribution of the entire population
downwards. The Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation (AD-
VANCE) study showed that this strategy reduced cardiovas-
cular death and coronary and renal events [11]. Finally, the
mean HbA1c in the intensive glucose control intervention
group in UKPDS was only maintained below 7% for the first
5 years of the study. Current guidelines include targets as
low as 6.5% in Europe and 7.0% in the USA [12, 13].
In the entire ADVANCE study, there was no risk
reduction of laser photocoagulation by blood pressure
lowering [11] or by intensive glucose control [14]. Here
we report the results of the ADVANCE Retinal Measure-
ments (AdRem) study, a substudy of ADVANCE, to
investigate effects on the incidence and progression of
retinopathy.
Methods
AdRem was performed in 39 centres in 14 countries in
Asia, Australia, Europe and North America. Approval for
A. Stanton
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the trial was obtained from the institutional review board of
each centre and all participants provided written informed
consent. The study design and the methods used in AdRem
are published in detail elsewhere [15] and briefly described
here. The study is registered with Clinicaltrials.gov, no.
NCT00145925.
Design ADVANCE was a 2×2 factorial, randomised
controlled trial in 11,140 type 2 diabetic patients receiving
standard care, as described elsewhere [16]. The primary
endpoints were composite measures of macro- and micro-
vascular disorders. After a 6 week run-in period on a fixed
combination tablet consisting of perindopril (2 mg) and
indapamide (0.625 mg) and usual glucose-lowering treat-
ment, eligible participants were randomly assigned in a
2×2 factorial design to one of four treatment combinations.
The two main effects comparisons were a double-blind
comparison of blood pressure-lowering vs placebo, and an
open comparison of gliclazide MR-based intensive glucose-
lowering regimen targeting an HbA1c of 6.5% or less vs
standard guideline-based glucose lowering using a prospec-
tive, randomised, open-label, blinded endpoint evaluation
design.
Setting and participants The ADVANCE study randomised
type 2 diabetic patients, diagnosed at the age of 30 years or
older and aged 55 years or older at study entry. Potentially
eligible patients were also required to have at least one
additional risk factor for cardiovascular disease [11, 16].
AdRem was conducted in study centres with access to
retinal cameras. In addition to the inclusion and exclusion
criteria of ADVANCE, patients were excluded from
AdRem if they had had a previous ophthalmological
intervention procedure (such as laser coagulation treatment
or vitrectomy) or if it was unlikely that good quality stereo
photographs could be taken, because of severe cataract or
pupils that did not dilate to at least 4 mm.
Randomisation and interventions The blood pressure-
lowering treatment was a fixed low-dose combination of
perindopril (2 mg doubled to 4 mg after 3 months) and
indapamide (0.625 mg doubled to 1.25 mg after 3 months).
For intensive glucose control, other oral glucose-lowering
agents and insulin were added to a long-acting sulfonylurea
(gliclazide MR 30 mg uptitrating to 120 mg as required),
over time at the discretion of the treating physician, to
achieve a target HbA1c of 6.5% or less. Study treatments
were randomly allocated using a central, computer-based
procedure, stratified by study centre, history of macro- or
microvascular disease and background use of perindopril at
baseline. The use of other concomitant treatments during
follow-up remained at the discretion of the treating
physician with some exceptions: the use of thiazide or
thiazide-like diuretics was not allowed, and open-label
perindopril, to a maximum of 4 mg a day, was the only
ACE inhibitor allowed, ensuring a maximum dose of 8 mg
perindopril; gliclazide MR was the only sulfonylurea
allowed in the intensive glucose control group; and
sulfonylureas except gliclazide were allowed in the stan-
dard glucose control group.
Photography Retinal photographs were taken after the
ADVANCE randomisation visit and at the final visit of
the blood pressure arm of the trial (completed 6 months
before the glucose arm) with a median interval of 2 months
(IQR 1–6 months). For those patients with photographs
taken within 3 months after the randomisation visit, another
photograph was taken at the visit 2 years after random-
isation. Seven standard field stereoscopic photographs of
the left and right eyes were taken with 35 mm high-quality
colour films (Kodak EPR64 135-36), according to the Early
Treatment of Diabetic Retinopathy Study (ETDRS) proto-
col [17]. The seven fields included one centred on the optic
disc, one centred on the macula, one temporal to the
macula, and two superior and two inferior fields. In patients
with non-gradeable images according to strict criteria [15],
repeat photographs were sought.
Retinopathy grading The ETDRS classification was slight-
ly modified in the UKPDS, and this modified classification
was used in the AdRem study [7]. Detected lesions were
graded in comparison with the ETDRS final scale standard
photographs. Retinal vascular lesions were also assessed in
each field using standard photographs [15]. All images
were graded centrally (at the University Medical Center
Utrecht) by two independent readers trained by the
Retinopathy Grading Center, Hammersmith Hospital, Im-
perial College London. Approximately 15% of the photo-
graphs were judged ungradeable throughout the study. If
there were discordant readings between the two readers,
this was solved in consensus in a meeting with both readers
and an experienced ophthalmologist. In 8.8% of the
gradeable photographs there was a discordant reading,
resulting in a kappa of 0.82.
Substudy outcomes The primary endpoint of the study was
progression of ≥2 steps in ETDRS classification with laser
coagulation therapy during follow-up as the final step in
ETDRS classification, including both incidence and pro-
gression of retinopathy. Secondary endpoints included ≥1
or ≥3 steps of progression in ETDRS classification,
incidence as a change of ≥2 steps and progression as a
change of ≥3 steps in ETDRS classification according to
the European Medicines Agency (EMEA) guideline, laser
coagulation therapy, each of the separate retinal vascular
lesions (arteriovenous nicking, microaneurysms, retinal
Diabetologia (2009) 52:2027–2036 2029
haemorrhages, cotton wool spots, hard exudates, macular
oedema), and any vascular lesion. Macular oedema was
defined as definite macular thickening within 1 disc
diameter from the centre of the macula, assessed in field 2
by stereoscopic viewing. This was the only outcome in the
study defined post hoc [7]. The score in the worst eye at
each assessment was used to calculate incidence and
progression. The presence of retinopathy at baseline was
defined as ETDRS ≥20.
Statistical analysis AdRem was designed to include 2,000
participants, which would have provided at least 85%
power with a two-tailed type I error of 5% to detect an
absolute reduction of 6% in the event rate of the primary
endpoint associated with both blood pressure lowering and
intensive glucose control. This assumed an event rate of
27.8% over 6 years of follow-up based on data from
UKPDS.
All analyses were based on the intention-to-treat
principle (1,241 patients with gradeable baseline and
final photographs). In the absence of a final retinal
photograph, available 2 year photographs were used.
Treatment effects in both arms for all endpoints were
estimated using logistic regression, adjusted for centre
and randomisation of the other treatment arm. When
differences in baseline characteristics were observed,
adjustment for those characteristics was conducted as a
secondary analysis. Differences in blood pressure and
changes in weighted HbA1c during the study between
treatment groups were analysed by analysis of variance
using a mixed model. The homogeneity of treatment
effects for several prespecified factors (the other treatment
arm, presence of retinopathy at baseline) was estimated by
including interaction terms in the logistic model. All
analyses were performed using SAS version 9.1 (SAS
Institute, Cary, NC, USA).
Results
The trial profile showed that 2,130 of the 2,863 eligible
patients consented to participate (Fig. 1). After further ex-
clusions (shown in Fig. 1), the study population comprised
1,602 patients. During follow-up, 324 photographs were
not received and 37 photographs were not gradeable,
loss of follow-up data being similar across treatment
arms. Finally, 1,241 patients with gradeable baseline and
final photographs were included in the intention-to-treat
analysis.
There were no clinically meaningful differences in
baseline characteristics between treatment groups in either
study arm (Table 1). At baseline, mean age was 65.6±
5.8 years, median duration of diabetes 6 years (2–11 years),
61.3% of the population was male and retinopathy (ETDRS
≥20) was present among 40.1% of patients. Systolic and
diastolic blood pressures (mean ± SD) were 142.7±21.7
and 79.3±10.8 mmHg, and HbA1c was 7.4±1.5%.
Baseline characteristics were well balanced across treat-
ment groups in both study arms among patients with valid
photographs at baseline and during follow-up, although
the presence of retinal haemorrhages was slightly higher
among those on intensive glucose-lowering therapy
(50.3%) than on standard therapy (43.9%). The study
population did not differ substantially compared with the
entire ADVANCE population, except for a slightly shorter
duration of diabetes.
Compared with placebo, active blood pressure-lowering
therapy gave a mean reduction in systolic blood pressure of
6.1±1.2 mmHg and diastolic blood pressure of 2.3±
0.6 mmHg (p<0.001 for both; Fig. 2a). Intensive glucose
control significantly reduced HbA1c from 7.4% to 6.5%,
whereas HbA1c remained unchanged with standard glucose
control (p<0.001; Fig. 2b). Use of insulin during follow-up
was more frequent among those randomised to intensive
glucose control (38.8%) compared with patients assigned
standard (20.8%) glucose control (p<0.001).
We documented progression of retinopathy in 59 (4.8%)
patients and incident retinopathy in 128 (10.3%) patients
during a median follow-up of 4.1 years. Fewer patients on
blood pressure-lowering therapy experienced new or
worsening retinopathy compared with those on placebo
(OR 0.78; 95% CI 0.57–1.06; p=0.12), but the difference
was not significant (Table 2). The absolute risk of incidence
and progression was 16.7% for placebo and 13.5% for
perindopril–indapamide treatment (risk difference, 3.2%).
Similar results were observed for progression of ≥3 steps in
the ETDRS classification and the endpoint definition
according to EMEA, while progression of ≥1 steps in the
ETDRS classification was not different between treatments.
The presence of any retinal vascular lesion was similar for
blood pressure-lowering and placebo (p=0.34), but active
therapy significantly reduced the presence of macular
oedema (OR 0.50; 95% CI 0.29–0.88; p=0.016) and
arteriovenous nicking (OR 0.60; 95% CI 0.38–0.94;
p=0.025) compared with placebo. These results were
largely unchanged when adjusted for the presence of
baseline retinal haemorrhages and were independent of
baseline systolic and diastolic blood pressure (OR 0.77;
95% CI 0.57–1.06 for ≥2 steps of progression). Regression
of retinopathy (≥2 steps in the ETDRS classification) was
not significantly different between blood pressure-lowering
and placebo treatment.
Intensive glucose-lowering treatment did not significant-
ly reduce the incidence and progression of retinopathy (OR
0.84; 95% CI 0.61–1.15; p=0.27; Table 2). The absolute
risk of incidence and progression was 16.2% for standard
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glucose control and 14.0% for intensive glucose control
(risk difference, 2.2%). Similar results were observed for
the incidence and progression of ≥1 steps, ≥3 steps and the
endpoint definition according to EMEA (Table 2). Similarly,
the presence of any retinal vascular lesion did not differ
between intensive glucose-lowering and usual treatment (OR
0.97; 95% CI 0.78–1.12; p=0.81), nor did any of the other
specified retinal vascular lesions differ. However, after adjust-
ing for the presence of retinal haemorrhages at baseline,
lower, albeit borderline significant, risks of arteriovenous
nicking, microaneurysms, retinal haemorrhages, hard exudates
and macular oedema were observed in the intensive glucose-
lowering arm. These results were independent of baseline
HbA1c concentration. Regression of retinopathy (≥2 steps in
ETDRS classification) was not significantly different between
intensive and standard glucose control treatments. Similar
results were observed among patients with a reduction of
HbA1c >0.5% in 6 months (OR 0.95; 95% CI 0.56–1.61),
although it should be noted that subgroup analyses based on
post-randomisation characteristics are potentially biased.
The effects of blood pressure lowering and intensive
glucose control were independent and additive, since no
significant interactions between the treatment arms were
observed. For example, the odds ratio for progression of ≥2
steps in ETDRS classification for perindopril–indapamide
and intensive glucose control against placebo and standard
glucose control was 0.66 (95% CI 0.43–1.02). The
corresponding odds ratio for macular oedema was 0.34
(95% CI 0.15–0.77) and that for arteriovenous nicking was
0.42 (95% CI 0.22–0.82).
Among patients without baseline retinopathy, odds ratios
for progression of ≥2 steps in retinopathy were slightly
lower for both blood pressure-lowering treatments (OR
0.74; 95% CI 0.50–1.08) and intensive glucose control (OR
0.75; 95% CI 0.49–1.07), although interaction terms did not
reach significance for any of the endpoints. Using higher
cut-off values to define presence of the specific vascular
lesions gave similar results. Only for arteriovenous nicking
were numbers of events too low using a higher cut-off
value to provide reliable data (data not shown).
Discussion
Both blood pressure lowering and intensive glucose control
produced consistent trends to benefits in patients with type 2
diabetes. These trends were independent of initial blood






No baseline photograph received (n=148) 
Baseline photographs received (n=1,982) 
Photograph not gradeable (n=374) 
Lasertherapy reported with photograph (n=6) 
Valid baseline photograph (n=1,602) 
Placebo (n=618) Perindopril–indapamide (n=623) Standard glucose control (n=611) Intensive glucose control (n=630) 
Intention to treat analysis (n=1,241) 
Missing follow-up photograph (n=324) 
Ungradeable follow-up photograph (n=37)
Fig. 1 Flowchart of patients in the AdRem study
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of HbA1c for the glucose control comparison. The reductions
observed were not statistically significant for either of the
interventions, although the incidence of some retinal
vascular lesions (for example, macular oedema) was reduced
in both arms of the trial.
Strengths of this study include its design and retinal
photography using seven-field stereoscopic retinal photog-
raphy of both eyes. The main limitation of this study is the
lower than planned sample size. Gradeable baseline and
follow-up photographs were intended to be obtained for
2,000 patients in AdRem [15]. Despite intensive efforts to
collect both baseline and follow-up photographs for all
patients, 37 photographs were ungradeable and 324 photo-
graphs were not received, leaving only 1,241 patients for
Table 1 Baseline characteristics of 1,602 type 2 diabetic patients in the AdRem study according to blood pressure-lowering treatment







n 796 806 811 791
Age (years) 65.6±5.9 65.6±5.8 65.6±5.7 65.6±6.0
Time of follow-up (years); median (IQR) 4.1 (3.7–4.3) 4.1 (3.7–4.3) 4.1 (3.7–4.3) 4.1 (3.7–4.3)
Sex (% female) 37.1 40.3 39.3 38.1
Ethnicity (%)
White 48.5 47.0 48.2 47.3
Chinese 37.9 38.3 36.7 39.6
South Asian 8.5 9.6 9.6 8.5
Duration of diabetes (years); median (IQR) 6 (2–11) 6 (2–11) 6 (2–11) 6 (2,11)
ETDRS classification level
10: diabetic retinopathy absent (%) 50.6 50.4 51.3 49.7
14: diabetic retinopathy questionable (%) 8.5 10.3 8.6 10.2
20: microaneurysms only (%) 22.4 21.8 22.0 22.3
35: mild non-proliferative diabetic retinopathy (%) 8.4 8.3 7.8 9.0
43: moderate non-proliferative diabetic retinopathy (%) 6.9 5.0 6.0 5.8
47: moderate or severe non-proliferative diabetic retinopathy (%) 1.8 1.6 1.6 1.8
53: severe non-proliferative diabetic retinopathy (%) 0.9 1.1 1.5 0.5
61–81: proliferative diabetic retinopathy (%) 0.5 1.5 1.2 0.8
ARIC classification
Arteriovenous crossing changes (nicking) (%) 11.1 8.6 9.3 10.4
Microaneurysms (%) 27.0 26.3 27.0 26.3
Retinal haemorrhages (%) 46.7 44.4 43.7 47.5
Cotton wool spots (soft exudates) (%) 27.3 25.0 25.8 26.4
Hard exudates (%) 15.1 17.6 15.8 16.9
Retinopathy (ETDRS ≥20) (%) 40.9 39.3 40.1 40.1
BMI (kg/m2) 27.7±4.7 27.7±4.9 27.6±4.8 27.8±4.8
HbA1c (%) 7.3±1.4 7.5±1.5 7.4±1.5 7.4±1.5
Glucose (mmol/l) 8.5±2.8 8.5±2.8 8.4±2.7 8.6±2.9
Systolic blood pressure (mmHg) 143.1±21.4 142.3±22.0 142.7±21.2 142.7±22.2
Diastolic blood pressure (mmHg) 79.5±10.5 79.2±11.2 79.0±10.8 79.6±10.9
Use of blood pressure-lowering agents (%) 69.1 70.4 71.0 68.4
History of hypertension (%) 64.2 65.3 65.1 64.4
Combined systolic and diastolic BP elevation (%) 53.5 53.0 53.6 52.8
Smoking (% yes) 15.6 13.2 14.3 14.4
Use of oral hypoglycaemic agents (%) 87.9 88.5 88.3 88.1
Use of insulin (%) 1.1 0.7 1.0 0.9
Data are mean ± SD unless otherwise indicated
ARIC, Atherosclerosis Risk in Communities [27]
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the primary analysis. In addition, our sample size
calculations assumed an event rate of 27.8% in the
standard glucose-lowering treatment groups, which ulti-
mately proved to be only 12.2%. This was probably
attributable to improved diabetes care since UKPDS, as
reflected by the higher background level of medication
use in our study population compared with the UKPDS
population [8, 11, 14].
A second limitation of this study is the quality assurance
of the photographs. Although we recorded disagreement
between the readers throughout the study, resulting in a
kappa value of 0.85, a formal quality assurance of intra-
reader agreement was not performed. This may have led to
random error in our data, particularly for results on the
occurrence of individual lesions. We used progression of ≥2
steps in ETDRS classification as the primary endpoint,
because one step of progression may still reflect measure-
ment error in these measures. Indeed, our results showed
stronger associations when using ≥2 steps of progression,
which was confirmed by a secondary analysis with ≥3 steps
of progression. Nevertheless, such random error may still
be present in our results and should be accounted for when
interpreting these data. However, assuming that the ob-
served relation is true, such random error can only have
attenuated the association.
The incidence and progression of retinopathy (as
assessed by ≥2 steps of progression in ETDRS classifica-
tion) tended to be lower after blood pressure-lowering
treatment compared with placebo after 4.1 years (OR 0.78;
95% CI 0.57–1.07). This risk reduction is similar to the
non-significant reduction of 25% in deterioration of ≥2
steps on the ETDRS scale reported by UKPDS after
4.5 years of follow-up (OR 0.75; 0.55–1.02) [10]. The risk
reduction in UKPDS increased to 34% after 7.5 years of
follow-up. It should be noted that the blood pressure
intervention in UKPDS was performed among a subgroup
of patients with diabetes and hypertension, whereas we
included patients irrespective of initial blood pressure level.
The initial blood pressures and mean blood pressure
reduction observed in AdRem are therefore much smaller
than those observed in the UKPDS [10]. However, after
4 years of follow-up similar results were observed;
significance was reached only after 7.5 years of follow-up
in the UKPDS. More recently, the DIabetic REtinopathy
Candesartan Trials (DIRECT-Protect 2) reported a non-
significant 13% relative reduction in retinopathy with
candesartan treatment compared with placebo among type
2 diabetic patients and background retinopathy, but regres-
sion of retinopathy occurred more often with candesartan
treatment [18]. These results differ from ours, because we
could not detect any effects on the regression of retinopathy
and progression seemed to be particularly reduced among
those without baseline retinopathy.
Macular oedema, which is the most common cause of
loss of vision in diabetic patients, was significantly reduced















































Fig. 2 Mean changes in (a)
systolic and diastolic blood
pressure during the study
according to blood pressure-
lowering treatment and (b) mean
HbA1c according to blood
glucose-lowering treatment
among 1,241 type 2 diabetic
patients in the AdRem study.
a squares, placebo; triangles,
perindopril–indapamide; differ-
ence in systolic blood pressure
(black squares/triangles): 6.1±
1.2 mmHg (p<0.001); differ-
ence in diastolic blood pressure
(white squares/triangles): 2.3±
0.6 mmHg (p<0.001).
b squares, standard glucose
control; triangles, intensive
glucose control; difference in
mean HbA1c, 0.7±0.1%;
p<0.001. R, randomisation
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Table 2 Odds ratios (95% CI) of incidence and progression of retinopathy for perindopril–indapamide treatment vs placebo and intensive vs
standard blood glucose-lowering treatment
Variable Placebo Perindopril–
indapamide





Progression of ≥2 steps in ETDRS classification
Cases 103 84 99 88
OR (95% CI) 1.0 0.78 (0.57–1.06) 0.12 1.0 0.84 (0.61–1.15) 0.27
Adjusted ORa (95% CI) 1.0 0.78 (0.57–1.06) 0.11 1.0 0.85 (0.62–1.16) 0.30
Progression of ≥1 steps in ETDRS classification
Cases 135 132 137 130
OR (95% CI) 1.0 0.96 (0.73–1.26) 0.77 1.0 0.90 (0.69–1.18) 0.44
Adjusted ORa (95% CI) 1.0 0.96 (0.73–1.26) 0.76 1.0 0.90 (0.69–1.18) 0.45
Progression of ≥3 steps in ETDRS classification, incidence of ≥2 steps (EMEA)
Cases 92 75 90 77
OR (95% CI) 1.0 0.78 (0.56–1.09) 0.14 1.0 0.81 (0.58–1.12) 0.20
Adjusted ORa (95% CI) 1.0 0.78 (0.56–1.08) 0.13 1.0 0.83 (0.60–1.15) 0.26
Progression of ≥3 steps in ETDRS classification
Cases 41 29 39 31
OR (95% CI) 1.0 0.68 (0.42–1.11) 0.13 1.0 0.76 (0.47–1.23) 0.26
Adjusted ORa (95% CI) 1.0 0.69 (0.42–1.12) 0.13 1.0 0.72 (0.44–1.17) 0.18
Laser coagulation therapy
Cases 18 20 22 16
HR (95% CI) 1.0 1.11 (0.58–2.12) 0.76 1.0 0.70 (0.36–1.34) 0.28
Adjusted HRa (95% CI) 1.0 1.13 (0.59–2.18) 0.71 1.0 0.62 (0.32–1.21) 0.16
Arteriovenous crossing changes (nicking)
Cases 53 33 49 37
OR (95% CI) 1.0 0.60 (0.38–0.94) 0.025 1.0 0.72 (0.46–1.11) 0.14
Adjusted ORa (95% CI) 1.0 0.60 (0.38–0.95) 0.030 1.0 0.66 (0.42–1.04) 0.074
Microaneurysms
Cases 176 163 176 163
OR (95% CI) 1.0 0.89 (0.69–1.15) 0.37 1.0 0.86 (0.67–1.10) 0.23
Adjusted ORa (95% CI) 1.0 0.91 (0.69–1.20) 0.52 1.0 0.73 (0.55–0.96) 0.025
Retinal haemorrhages
Cases 305 288 300 293
OR (95% CI) 1.0 0.89 (0.71–1.12) 0.31 1.0 0.89 (0.72–1.13) 0.35
Adjusted ORa (95% CI) 1.0 0.91 (0.71–1.17) 0.46 1.0 0.78 (0.61–1.01) 0.055
Cotton wool spots (soft exudates)
Cases 96 84 86 94
OR (95% CI) 1.0 0.84 (0.61–1.16) 0.29 1.0 1.07 (0.78–1.47) 0.67
Adjusted ORa (95% CI) 1.0 0.86 (0.62–1.20) 0.38 1.0 0.98 (0.70–1.36) 0.88
Hard exudates
Cases 81 92 95 78
OR (95% CI) 1.0 1.14 (0.82–1.58) 0.43 1.0 0.76 (0.55–1.06) 0.10
Adjusted ORa (95% CI) 1.0 1.20 (0.85–1.69) 0.29 1.0 0.66 (0.47–0.94) 0.019
Macular oedema
Cases 37 20 33 24
OR (95% CI) 1.0 0.50 (0.29–0.88) 0.016 1.0 0.69 (0.40–1.18) 0.17
Adjusted ORa (95% CI) 1.0 0.50 (0.28–0.89) 0.018 1.0 0.59 (0.34–1.03) 0.065
Any retinal vascular lesion
Cases 329 313 318 324
OR (95% CI) 1.0 0.90 (0.72–1.12) 0.34 1.0 0.97 (0.78–1.22) 0.81
Adjusted ORa (95% CI) 1.0 0.92 (0.72–1.17) 0.48 1.0 0.87 (0.68–1.12) 0.28
a Adjusted for presence of retinal haemorrhages at baseline
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nicking was also reduced after blood pressure-lowering
treatment, but similar reductions were not apparent for
other lesions. Arteriovenous nicking and macular oedema
have both been associated with hypertension and endothe-
lial dysfunction [19, 20], providing a possible mechanistic
explanation for these findings. The occurrence of vascular
changes also predicts progression of retinopathy [21]. We
could not detect any risk reduction in laser coagulation
therapy of blood pressure-lowering treatment, in keeping
with the entire ADVANCE study [11]. These results are
also consistent with observations among diabetic patients in
the Heart Outcomes Prevention Evaluation (HOPE) study
showing no significant reduction in laser coagulation
therapy after ramipril treatment, but the studies may not
be comparable as HOPE was conducted in the mid-1990s
[22]. These findings contrast with the results of UKPDS,
which showed a reduction of one-third in retinopathy, which
mainly consisted of a reduction in laser coagulation therapy
[9]. These inconsistencies may be attributable to the fact that
laser coagulation therapy is an insensitive but specific marker
of the progression of retinopathy, which is influenced by
treatment practice or healthcare access. Furthermore, dis-
crepancies between our findings and those of UKPDS could
reflect the shorter duration of treatment and better levels of
glycaemic, blood pressure and lipid control in ADVANCE,
contributing to slower progression of retinopathy.
Intensive blood glucose-lowering treatment did not
significantly affect the incidence and progression of
retinopathy, although the presence of several retinal
vascular lesions tended to be lower among the intensively
treated group compared with the group receiving standard
treatment. This is consistent with results in the first years of
follow-up in UKPDS. After only 3 years of follow-up,
UKPDS observed a relative risk of intensive vs conven-
tional glucose control of 1.03 (99% CI 0.79–1.34) for
progression of ≥2 steps in ETDRS classification. This
relative risk was only 0.83 (95% CI 0.67–1.01) after both 6
and 9 years of follow-up, while only after 12 years of
follow-up was a borderline significant relative risk of 0.79
(0.63–1.00) observed [8]. For a combined endpoint of
microvascular endpoints, the UKPDS recorded a 25%
reduction in more than 10 years of follow-up, most of
which was attributable to a reduction in cases of retinal
photocoagulation [8]. In addition, the Veterans Affairs
Diabetes Trial did not detect any reduction in the incidence
or progression of retinopathy after intensive glucose-
lowering treatment [23]. Among type 1 diabetic patients, a
similar risk reduction of retinopathy was found in the
Diabetes Control and Complications Study over 6.5 years
[24]. This risk reduction persisted for 4 years after
termination of the trial [25]. Similarly, the UKPDS recently
reported that, despite a loss of glycaemic differences, the
reduced risk of microvascular disease continued and risk
reductions for myocardial infarction and death emerged
during 10 years of post-trial follow-up [26]. Altogether,
these studies suggest that a longer period is needed for
intensive glucose control to result in clinically relevant risk
reductions in retinopathy. The presence of certain retinal
vascular lesions, such as macular oedema and micro-
aneurysms, tended to be reduced after intensive glucose-
lowering treatment. Since vascular changes predict the
progression of retinopathy [21], these changes may herald
reduced progression of retinopathy. However, longer
follow-up is needed to establish this.
In conclusion, the AdRem Study could not demonstrate
significant reductions in retinopathy either with blood
pressure-lowering treatment or with intensive glucose
control. Nevertheless, there were clear trends to reduction
in the incidence and progression of retinopathy by ≥2 steps
in the ETDRS classification, for blood pressure lowering
with the fixed combination of perindopril and indapamide,
and for intensive glucose control with the gliclazide MR-
based regimen, in type 2 diabetic patients. These trends
were supported by the reduced incidence of retinal vascular
lesions and were independent of initial blood pressures or
HbA1c. A longer period of active treatment and larger
numbers of patients are needed to demonstrate more
definitive benefits.
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